Share-based Payment Arrangement, Expense of Centessa Pharmaceuticals plc from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Centessa Pharmaceuticals plc quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • Centessa Pharmaceuticals plc Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $7,194,000, a 15% decline year-over-year.
  • Centessa Pharmaceuticals plc Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $31,354,000, a 4% decline year-over-year.
  • Centessa Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2024 was $33,546,000, a 14% increase from 2023.
  • Centessa Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2023 was $29,392,000, a 18% increase from 2022.
  • Centessa Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2022 was $24,965,000, a 68% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Centessa Pharmaceuticals plc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $31,354,000 $7,194,000 -$1,259,000 -15% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $32,613,000 $7,949,000 -$662,000 -7.7% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $33,275,000 $7,883,000 -$271,000 -3.3% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $33,546,000 $8,328,000 +$898,000 +12% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $32,648,000 $8,453,000 +$894,000 +12% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $31,754,000 $8,611,000 +$1,398,000 +19% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $30,356,000 $8,154,000 +$964,000 +13% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $29,392,000 $7,430,000 +$813,000 +12% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $28,579,000 $7,559,000 +$532,000 +7.6% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $28,047,000 $7,213,000 +$1,610,000 +29% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $26,437,000 $7,190,000 +$1,472,000 +26% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $24,965,000 $6,617,000 +$1,858,000 +39% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $23,107,000 $7,027,000 +$2,894,000 +70% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $20,213,000 $5,603,000 +$2,374,000 +74% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $17,839,000 $5,718,000 +$2,987,000 +109% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $14,852,000 $4,759,000 +$4,759,000 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $10,093,000 $4,133,000 +$4,104,000 +14152% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $5,989,000 $3,229,000 +$3,139,000 +3488% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $2,850,000 $2,731,000 30 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $0 01 Jan 2021 29 Jan 2021 10-K 30 Mar 2023 2022 FY
Q3 2020 $29,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $90,000 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2

Centessa Pharmaceuticals plc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $33,546,000 +$4,154,000 +14% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $29,392,000 +$4,427,000 +18% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $24,965,000 +$10,113,000 +68% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $14,852,000 +$14,516,000 +4320% 30 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $336,000 +$100,000 +42% 01 Jan 2020 31 Dec 2020 10-K 30 Mar 2022 2021 FY
2019 $236,000 01 Jan 2019 31 Dec 2019 10-K 30 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.